サポート>ブログ>VHHライブラリ作製

VHHライブラリ作製

Biointron 2024-01-26

VHH-Library-Generation.jpg

VHHs, also known as single-domain antibodies or nanobodies, are the smallest antigen-binding fragments derived from heavy-chain-only antibodies found in camelids, such as alpacas, llamas and camels. First discovered in 1993, VHH antibody fragments offer unique characteristics which are particularly advantageous in therapeutics, diagnostics, and research tools. This is due to their small size and structure which allows them to penetrate tissues and reach targets that may be challenging for conventional antibodies, in addition to their stability and ability to bind with high affinity to specific targets.1


VHH Library Generation 

There are several ways to isolate VHHs from camelids against a target of interest and to build a library for screening, such as immunized, naïve, and synthetic/semi-synthetic libraries. The most common approach is by immunizing camelids and building a library based on the repertoire of heavy-chain immunoglobulins.2,3 The process is as follows: 

  1. Camelid immunization: In 2 months, camelids are injected four to eight times with target antigens. 

  2. PBMC isolation: Peripheral blood samples are collected, and peripheral blood mononuclear cells are separated. 

  3. mRNA extraction and reverse transcription: mRNA is converted into cDNA. 

  4. Phage library generation: PCR is used to amplify the VHH gene regions. 

  5. Biopanning and library screening. 

  6. Positive clone sequencing and sequence analysis. 

  7. VHH expression and purification. 

  

At Biointron, we are dedicated to accelerating antibody discovery, optimization, and production. Our team of experts can provide customized solutions that meet your specific research needs. Contact us to learn more about our services and how we can help accelerate your research and drug development projects. 


References:

  1. Hamers-Casterman, C., Atarhouch, T., Muyldermans, S., Robinson, G., Hamers, C., Songa, E. B., Bendahman, N., & Hamers, R. (1993). Naturally occurring antibodies devoid of light chains. Nature, 363(6428), 446–448. https://doi.org/10.1038/363446a0

  2. Arbabi-Ghahroudi, M. (2022). Camelid Single-Domain Antibodies: Promises and Challenges as Lifesaving Treatments. International Journal of Molecular Sciences, 23(9). https://doi.org/10.3390/ijms23095009

  3. Muyldermans, S. (2021). A guide to: Generation and design of nanobodies. The Febs Journal, 288(7), 2084-2102. https://doi.org/10.1111/febs.15515

Subscribe to our ブログ
Recommended Articles
人間の免疫システムの活用:自然な防御から精密医療へ

免疫・PAMP/DAMP・革新的抗体療法の解説

Aug 08, 2025
抗体薬物複合体(ADC)の基礎レビュー:作用機序、臨床進展、設計最適化、課題、および将来

抗体薬物複合体(Antibody-Drug Conjugates, ADC)は、がん治療において革新的なターゲット型治療薬の一つであり、モノクローナル抗体(mA……

Aug 05, 2025
抗体機能におけるFc糖鎖の役割

抗体の機能は、Fc領域の糖鎖修飾状態に大きく依存しています。

Jun 25, 2025
AIS 2025 – フランス:ハイライトとイベント総括

第13回抗体産業シンポジウム(Antibody Industrial Symposium 2025)が、2025年6月25日から26日にかけてフランス・トゥール……

Jun 22, 2025

お客様の利便性を向上させるためにクッキーを使用しています。詳しくは プライバシーポリシー をご覧ください。